VRTX - Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) — 7-10yr sleeve. TRIKAFTA and KAFTRIO cover roughly 90% of the cystic fibrosis patient population globally, anchored by chronic lifelong therapy across approximately 88,000 patients in reimbursed markets at a $12 billion revenue base. The framework’s thesis rests on a structural CF monopoly with no approved mechanistic competitor and patent protection extending into the 2030s. Competitive context: AbbVie discontinued its CFTR programme, leaving Vertex unchallenged in CF mechanism; the non-CF pipeline enters a competitive IgA nephropathy landscape. Sleeve assignment reflects all five criteria met at maximum confidence — VRTX is the benchmark — with compounding optionality constrained at this scale, where incremental upside comes from non-CF pipeline execution. Named risk: the CF patent cliff begins in the early 2030s; the framework monitors European patent proceedings as the primary signal.

The BioCompound is a research publication. Nothing here constitutes investment advice.